Literature DB >> 32966770

Gene Editing Thumbs a Ride with Oncolytic Virotherapy.

Pin-Yi Wang1, Timothy P Cripe2.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32966770      PMCID： PMC7544997          DOI： 10.1016/j.ymthe.2020.09.016

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  5 in total

Review 1.  Acute Lymphoblastic Leukemia in Children.

Authors:  Stephen P Hunger; Charles G Mullighan
Journal:  N Engl J Med       Date:  2015-10-15       Impact factor: 91.245

Review 2.  Immunity to CRISPR Cas9 and Cas12a therapeutics.

Authors:  Wei Leong Chew
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2017-10-30

3.  Oncolytic Virus-Mediated RAS Targeting in Rhabdomyosarcoma.

Authors:  Michael P Phelps; Heechang Yang; Shivani Patel; Masmudur M Rahman; Grant McFadden; Eleanor Chen
Journal:  Mol Ther Oncolytics       Date:  2018-09-15       Impact factor: 7.200

4.  Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.

Authors:  Tamaki Yahata; Mika Mizoguchi; Akihiko Kimura; Takashi Orimo; Saori Toujima; Yumi Kuninaka; Mizuho Nosaka; Yuko Ishida; Izumi Sasaki; Yuri Fukuda-Ohta; Hiroaki Hemmi; Naoyuki Iwahashi; Tomoko Noguchi; Tsuneyasu Kaisho; Toshikazu Kondo; Kazuhiko Ino
Journal:  Cancer Sci       Date:  2019-02-27       Impact factor: 6.716
  5 in total
  1 in total

Review 1.  Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical.

Authors:  Chao Tang; Lan Li; Tong Mo; Jintong Na; Zhangbo Qian; Dianfa Fan; Xinjun Sun; Min Yao; Lina Pan; Yong Huang; Liping Zhong
Journal:  Clin Transl Oncol       Date:  2022-05-25       Impact factor: 3.340
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.